Summary
Nuvalent Stock Soars on $10.6 Billion GSK Buyout
Nuvalent Inc (NASDAQ:NUVL) is soaring in premarket trading, up 38.9% to trade at $122.88, after London-based GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion.
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal
Nuvalent is positioned as a high-quality late-stage biotech with two near-commercial precision oncology assets, not a traditional value play. NUVL's robust $1.37B cash position and recent $500M raise provide operational runway through 2029, supporting commercialization and expansion without near-term financing risk. Zidesamtinib's NDA for ROS1-positive NSCLC is accepted with a PDUFA date of September 2026; neladalkib NDA submission is planned for 1H 2026, targeting major unmet needs.
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in Nuvalent (NUVL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nuvalent, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 53 | $4,212.99 | $6,569.88 | $2,356.89 | 55.94% |
 Farallon Capital Farallon Capital Management LLC | 3,000 | $306,900 | $371,880 | $64,980 | 21.17% |
| BG Bart Gancher Intech Investment Management LLC | 12,296 | $973,532.49 | $1.52M | $550,679.67 | 56.57% |
 Bridgewater Associates LP Bridgewater Associates LP | 15,020 | $1.3M | $1.86M | $562,949.84 | 43.34% |
 David Kim Paradigm Biocapital Advisors LP | 5.32M | $362.24M | $660.02M | $297.78M | 82.21% |
Nuvalent, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EFV Eva Fortea Verdejo Wells Fargo | 72.17 | $6,979.85 | $8,945.64 | $1,965.79 | 28.16% |
Nuvalent, Inc. (NUVL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nuvalent, Inc. ever had a stock split?
Nuvalent, Inc. Profile
| Biotechnology Industry | Healthcare Sector | James R. Porter CEO | NASDAQ (NGS) Exchange | 670703107 CUSIP |
| US Country | 234 Employees | - Last Dividend | - Last Split | 29 Jul 2021 IPO Date |
Overview
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on the innovative development of targeted therapies for patients battling cancer. Established in 2017 and based in Cambridge, Massachusetts, the company is at the forefront of addressing some of the most critical challenges in cancer treatment. Through its dedication to science and patient care, Nuvalent is working on pioneering solutions for overcoming treatment resistance, managing central nervous system (CNS)-related adverse effects, and tackling the issue of brain metastases in cancer patients. Their research and development pipeline are primarily concentrated on creating highly selective inhibitors designed to improve the safety and efficacy profiles of existing treatments, thereby potentially extending both the quality and duration of life for patients with specific cancer types.
Products and Services
Nuvalent has a robust portfolio of product candidates, each targeting critical needs in oncology, particularly for lung cancer and other malignancies with specific genetic profiles. These include:
- NVL-520: This novel ROS1-selective inhibitor is engineered to overcome emergent treatment resistance, reduce CNS-related side effects, and address brain metastases in patients with ROS1-positive non-small cell lung cancer (NSCLC). It aims to provide a more effective treatment option where current ROS1 tyrosine kinase inhibitors (TKIs) fall short. NVL-520 is currently undergoing the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial.
- NVL-655: A brain-penetrant ALK-selective inhibitor, NVL-655 targets emergent treatment resistance and aims to reduce CNS-related adverse events and effectively manage brain metastases. This inhibitor is designed to offer an improved treatment alternative for patients encountering limitations with first-, second-, and third-generation ALK inhibitors. It is presently under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial.
- NVL-330: This product candidate is a human epidermal growth factor receptor 2 (HER2)-selective inhibitor focused on treating tumors driven by HER2ex20 mutations, managing brain metastases, and minimizing treatment-limiting adverse events, including the off-target inhibition of wild-type EGFR. NVL-330, notably brain-penetrant, is expected to enter phase 1 trials, demonstrating the company's commitment to advancing care for HER2-positive cancer patients.
